Teleflex (NYSE: TFX) divests OEM business for $1.5B and targets debt cut
Rhea-AI Filing Summary
Teleflex Incorporated completed the previously announced divestiture of its Original Equipment Manufacturing and Development Services business to Lotus US Bidco Inc. on August 3, 2026, for $1.5 billion in cash, subject to purchase price adjustments under the equity purchase agreement.
Teleflex estimates after‑tax proceeds of approximately $1.25 billion and states an intent to use the net proceeds to reduce debt by $800 million and help complete its $1 billion share repurchase authorization. At closing, the parties also entered a transition services agreement, a development and manufacturing agreement and a long‑term supply agreement to support ongoing product development and supply. Pro forma financial information reflecting the divestiture will be filed by amendment within four business days of closing, and Teleflex plans to provide updated 2026 financial guidance when it reports second‑quarter results on August 6, 2026.
Positive
- Completed strategic divestiture of the OEM business for $1.5 billion in cash, significantly increasing financial flexibility.
- Expects after‑tax proceeds of about $1.25 billion, with plans for $800 million debt reduction and support for a $1 billion share repurchase authorization.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 2.01, 7.01, 9.01
3 items
Item 2.01
Completion of Acquisition or Disposition of Assets
Financial
The company completed a significant acquisition or sale of business assets.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
OEM business sale price: $1,500,000,000 in cash
Estimated after-tax proceeds: approximately $1.25 billion
Planned debt reduction: $800 million
+3 more
6 metrics
OEM business sale price
$1,500,000,000 in cash
Consideration for the OEM Business divested on August 3, 2026
Estimated after-tax proceeds
approximately $1.25 billion
Teleflex’s estimate of net proceeds from the OEM divestiture
Planned debt reduction
$800 million
Amount Teleflex plans to pay down using divestiture proceeds
Share repurchase authorization
$1 billion
Existing authorization Teleflex aims to complete using proceeds
Pro forma filing deadline
four business days
Time frame to file pro forma financial information after closing
Closing date of OEM divestiture
August 3, 2026
Date Teleflex completed the OEM Business sale
Key Terms
transition services agreement, development and manufacturing agreement, long-term supply agreement, pro forma financial information, +1 more
5 terms
transition services agreement regulatory
"including (a) a transition services agreement, pursuant to which the Company will provide"
A transition services agreement is a formal arrangement where one company continues to provide essential services—such as IT, human resources, or accounting—to another company after a business deal or change in ownership. It acts like a temporary bridge, ensuring smooth operations during a transition period. For investors, it provides clarity on how long support will last and helps assess potential costs and stability during the change.
development and manufacturing agreement regulatory
"b) a development and manufacturing agreement, pursuant to which, amongst other things"
long-term supply agreement regulatory
"c) a long-term supply agreement, pursuant to which the OEM Purchaser or an affiliate"
pro forma financial information financial
"(b) Pro forma financial information The pro forma financial information required"
Pro forma financial information are adjusted financial numbers that show how a company’s results might look after a specific event or after removing one-time items, like a cleaned-up or “what if” version of its earnings. Investors use these figures to compare performance, judge future profitability, or evaluate the impact of mergers, restructurings or large transactions, but they require scrutiny because adjustments can make results look rosier than standard accounting statements.
forward-looking statements regulatory
"Certain statements made in this on , other than statements of historical fact, are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction did Teleflex (TFX) complete on August 3, 2026?
Teleflex completed the sale of its Original Equipment Manufacturing and Development Services business to Lotus US Bidco Inc. for $1.5 billion in cash, marking a major step in its portfolio transformation strategy.
How much cash did Teleflex (TFX) receive for its OEM business?
The OEM business was sold for a purchase price of $1.5 billion in cash. Teleflex estimates after‑tax proceeds of approximately $1.25 billion, reflecting expected taxes and transaction‑related adjustments under the equity purchase agreement.
How will Teleflex (TFX) use the proceeds from the OEM divestiture?
Teleflex intends to use net proceeds to reduce debt by $800 million and to help complete its $1 billion share repurchase authorization, returning capital to shareholders while supporting its broader growth strategy.
What ongoing agreements did Teleflex (TFX) sign with the OEM buyer?
At closing, Teleflex and the buyer entered a transition services agreement, a development and manufacturing agreement, and a long‑term supply agreement, providing for post‑closing support, product development and ongoing manufacturing and supply arrangements.
When will Teleflex (TFX) provide updated 2026 guidance and pro forma financials?
Teleflex plans to provide updated 2026 financial guidance when it reports second‑quarter results on August 6, 2026, and to file pro forma financial information by amendment within four business days after the August 3, 2026 closing.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| Date of Report (Date of Earliest Event Reported) | |||||
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
| Registrant’s Telephone Number, Including Area Code | ||||||||||||||
| Not applicable | ||
| (Former Name or Former Address, If Changed Since Last Report) | ||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.01 Completion of Acquisition or Disposition of Assets.
On August 3, 2026 (the “Closing Date”), Teleflex Incorporated (the “Company”) completed the previously announced sale of its Original Equipment Manufacturing and Development Services business (the “OEM Business”) to Lotus US Bidco Inc., a Delaware corporation (the “OEM Purchaser”), pursuant to the Equity Purchase Agreement, dated December 9, 2025 (the “OEM Agreement”), by and between the Company and the OEM Purchaser (the “OEM Transaction”).
In connection with the consummation of the OEM Transaction, the OEM Purchaser acquired the OEM Business from the Company for a purchase price of $1,500,000,000 in cash, subject to adjustment as contemplated in the OEM Agreement. In addition, on the Closing Date, the Company and the OEM Purchaser (or an affiliate thereof) entered into certain ancillary commercial agreements, including (a) a transition services agreement, pursuant to which the Company will provide, or cause to be provided, specified transition services for the benefit of the OEM Business for a specified period following closing, (b) a development and manufacturing agreement, pursuant to which, amongst other things, an affiliate of the OEM Purchaser will develop and manufacture a specified product for the Company for a specified period following closing and (c) a long-term supply agreement, pursuant to which the OEM Purchaser or an affiliate thereof will manufacture and supply certain products to the Company for a specified period following closing.
The foregoing description of the OEM Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by the full text of the OEM Agreement, a copy of which was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 9, 2025, and is incorporated by reference herein.
Item 7.01 Regulation FD Disclosure.
On the Closing Date and in connection with the consummation of the OEM Transaction, the Company issued a press release, which is furnished hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(b) Pro forma financial information
The pro forma financial information required by this item will be filed by amendment to this Current Report on Form 8-K not later than four business days after the Closing Date.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 2.1 | Equity Purchase Agreement, dated December 9, 2025, by and between the Company and Lotus US Bidco Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on December 9, 2025). | |||||||
| 99.1 | Press Release, dated August 3, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
Forward-Looking Statements
Certain statements made in this Current Report on Form 8-K, other than statements of historical fact, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “guidance,” “potential,” “continue,” “project,” “forecast,” “confident,” “prospects” and similar expressions typically are used to identify forward-looking statements. These statements include, but are not limited to, statements related to the transactions and expectations regarding certain ancillary commercial agreements entered into upon consummation of the OEM Transaction. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the Company’s business and the industry and markets in which the Company operates. These statements are not guarantees of future performance and are subject to risks and uncertainties, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements due to a number of factors, including unanticipated difficulties and expenditures in connection with integration programs; customer and shareholder reaction to the strategic divestiture; disruption from the strategic divestiture that may make it more difficult to maintain business and operational relationships; significant transaction costs; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions. For a further discussion of the risks relating to the Company’s business, see Part I, Item 1A, Risk Factors, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and Part II, Item 1A, Risk Factors, in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The Company expressly disclaims any obligation to update these forward-looking statements, except as otherwise explicitly stated by the Company or as required by law or regulation.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 3, 2026 | TELEFLEX INCORPORATED By: /s/ Jason Weidman Name: Jason Weidman Title: President and Chief Executive Officer | ||||
Exhibit 99.1
Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion
Intends To Utilize Net Proceeds To Pay Down Debt and Repurchase Shares
Wayne, Pa., August 3, 2026 - Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has completed the previously disclosed divestiture of its OEM business to Montagu and Kohlberg, for $1.5 billion in cash.
The close of the OEM transaction marks a pivotal milestone in Teleflex's transformation strategy, sharpening the Company's focus on the commercial excellence of its continuing businesses.
The divestiture strengthens Teleflex's financial flexibility and positions it to accelerate innovation and drive sustainable, profitable growth while returning significant capital to shareholders. Further, it allows the OEM business to benefit from dedicated resources to build on its established capabilities as an independent company under new ownership.
The company remains committed to its capital deployment priorities, including debt reduction of $800 million and completing its $1 billion share repurchase authorization. Consistent with this commitment, Teleflex intends to utilize the net proceeds from the close of the OEM strategic divestiture to return significant capital to shareholders through debt paydown and share repurchases, enhancing its financial flexibility to support its growth strategy.
Under the terms of the agreement, Teleflex estimates after tax proceeds of approximately $1.25 billion for its OEM business.
Teleflex will provide updated 2026 financial guidance when it reports second-quarter financial results on August 6, 2026.
Advisors
Centerview Partners LLC is serving as financial advisor, Simpson Thacher & Bartlett LLP is acting as legal counsel and Joele Frank is serving as strategic communications advisor to Teleflex.
Kirkland & Ellis LLP and Ropes & Gray LLP are acting as legal counsel to Montagu and Kohlberg.
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
CAUTION: Federal (USA) law restricts these devices for sale or use by or on the order of a physician.
Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S. and/or other countries. Other names are the trademarks of their respective owners. Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings, and precautions. Information in this document is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative.
© 2026 Teleflex Incorporated. All rights reserved.
Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836